[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics insider transactions by director Emma Reeve show multiple share sales and option exercises on 09/11/2025 under a pre-established Rule 10b5-1 plan. The filing discloses exercises of stock options to acquire 10,000 shares at a $25.69 exercise price and 837 shares at $33.63, both currently exercisable. Concurrently, there are several open-market sales executed at $59.50 per share (including sales of 3,534; 1,334; 10,000; and 837 shares in separate line items). The reporting person adopted the 10b5-1 plan on March 4, 2025. After the reported transactions the filing shows beneficial ownership snapshots, with one line indicating 10,332 shares beneficially owned following certain sales and other lines reflecting different post-transaction totals where option exercises increased holdings.

Positive

• Transactions executed under a documented Rule 10b5-1 plan, adopted March 4, 2025, which provides pre-clearance and defensible timing
• Exercises of vested options (10,000 shares at $25.69 and 837 shares at $33.63) converting options into common stock

Negative

• Significant share sales at $59.50 (multiple line items), which reduce the director's direct holdings as shown in post-transaction snapshots
• Filing does not state aggregate percentage of outstanding shares represented by the transactions, limiting assessment of materiality

Insights

Financial Analyst

TL;DR: Director executed option exercises and sold shares under a 10b5-1 plan, crystallizing gains at $59.50 while increasing exercised holdings.

The transactions are routine for executives monetizing through a pre-established plan while exercising vested options. The exercises at $25.69 and $33.63 converted in-the-money options into common shares, then multiple sales at $59.50 realized value. This pattern suggests planned liquidity rather than opportunistic trades tied to undisclosed events, given the explicit 10b5-1 plan adoption date of March 4, 2025. Materiality to investors is limited absent magnitude relative to total outstanding shares or company-specific undisclosed information.

Corporate Governance Expert

TL;DR: Trades were executed under a documented 10b5-1 plan and appear compliant; disclosure is standard and timely.

The Form 4 lists a clear Rule 10b5-1 plan and shows contemporaneous option exercises and market sales. From a governance standpoint, use of a 10b5-1 plan reduces insider trading risk and provides defensible timing for transactions. The filing is signed by an attorney-in-fact, consistent with delegated filing practice. No governance red flags are evident in the filing text alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Reeve Emma

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		S(1)		3,534	D	$59.5	11,666	D
Common Stock	09/11/2025		S(1)		1,334	D	$59.5	10,332	D
Common Stock	09/11/2025		M(1)		10,000	A	$25.69	20,332	D
Common Stock	09/11/2025		S(1)		10,000	D	$59.5	10,332	D
Common Stock	09/11/2025		M(1)		837	A	$33.63	11,169	D
Common Stock	09/11/2025		S(1)		837	D	$59.5	10,332	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.69	09/11/2025		M(1)			10,000	(2)	02/14/2034	Common Stock	10,000	$0	0	D
Stock Option (Right to Buy)	$33.63	09/11/2025		M(1)			837	(2)	12/13/2028	Common Stock	837	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did Emma Reeve report on the PTCT Form 4?

The filing reports option exercises to acquire 10,000 shares at $25.69 and 837 shares at $33.63, plus multiple sales executed at $59.50 per share on 09/11/2025.

Were these transactions part of a 10b5-1 trading plan for PTCT insiders?

Yes. The filing states the transactions were effected pursuant to a written Rule 10b5-1 plan adopted on March 4, 2025.

How many shares did the reporting person own after the transactions?

The Form 4 shows post-transaction beneficial ownership snapshots including a line showing 10,332 shares beneficially owned after certain reported sales; other lines reflect different totals after exercises.

What prices were involved in the reported PTCT transactions?

Option exercises had exercise prices of $25.69 and $33.63; multiple open-market sales were executed at $59.50 per share.

Is there any indication of accelerated vesting or special awards in this Form 4?

No. The filing only discloses standard option exercises and sales under the 10b5-1 plan and notes the exercised options are currently exercisable.